Voluncis, a pioneer company in the therapeutic accompanying software that gives power to patients for their self-treatment of chronic diseases, has received the FDA 510 (K) permission, in addition to the CE brand, for Insulia®.
This global digital solution, which is a scoop in its class, is compatible with the effective treatment of type 2 diabetes in adults treated with basal insulin.
People with type 2 diabetes are treated with basal insulin.Despite being supplied with effective medications, more than half of them do not meet the recommended objectives for glycemic control.
The main contributing factors include challenges with the beginning of insulin and valuation.Due to the complications associated with diabetes, its total annual cost in the United States reaches 300,000 million dollars.
Optimizing adherence to diabetes medications is recognized as one of the most effective ways to control disease expenses.The opportunity for savings in the United States is estimated at 4,690 (1) dollars per patient and year.
Insulia® Diabetes Management Companion is a medical device only by prescription that provides patients with insulin dose recommendations and teaching training messages in response to blood glucose values and other diabetes related data.
Insulia® is compatible with a wide variety of treatment plan and insulin adjustment standards based on the tests used in routine medical practices.
First, doctors establish a personalized treatment plan based on the patient's profile, prescription of insulin and blood glucose objectives.This allows Insulia® to provide automated insulin dose recommendations for the patient.
The dose adjustment algorithm is integrated into the application, being accessible to the patient by means of a web portal or through smartphones and iOS and Android tablets.Patient data are automatically shared with the health care equipment, which can remotely control the patient's progress towards their target thanks to the notifications intended.This allows suppliers to deploy widely personalized telemedicine services, an increasingly supported practice by payers worldwide.
"Type 2 diabetes is a complex disease, especially for people who have made change to insulin therapy. Insoline.manage and difficult for most patients.
As a result, adhering to new reliable technologies for the support of patients in the safe treatment of insulin doses while in contact with the health care team could be received correctly through the supplier and communitiesof patients, "said Ananda Basu, MBBS, Doctor and Endocrine of Mayic Clinic, Rochester, MN.
"To have an outstanding impact on the daily lives of patients, in addition to clinical results, we need to use intelligent digital solutions that go beyond data shared between patients and doctors. This is the reason why Ceritd andVoluntis have been working together for more than 10 years, designing and evaluating software that provides automated recommendations and support for clinical decisions to deal with diabetes care and take it to the next level, "said Guillaume Charpentier, doctor, endocrine and general director of the general director of theCeritd (Research Center for the Intensification of Diabetes Treatment).
"With accompaniment software, we seek to contribute to the transition to careBased on value, through the improvement of the quality of care and optimization of the treatment costs of chronic diseases, "said Pierre Leurent, founder and CEO of Volunz." This simultaneous regulatory permit of Insulia®, both inThe United States as in Europe, is a unique achievement within digital health and the culmination of numerous years of hard work.We are impatient to work hand in hand with suppliers and payers, in addition to business partners, to make this innovative solution widely available for patients around the world. "
Insulia® will be available for patients and health care providers in the first half of 2017.
About volunteers
The pioneer therapeutic software of accompaniment of voluntis innova within the field of health through the integration of connectivity within medical and therapeutic intelligence in software.Dedicated to the treatment of chronic diseases, voluntis accompaniment software aims to achieve treatment customization that supports the coordination of equipment care and improves the results of the real world.Adhering to its own technology, Voluncis has developed digital solutions for diabetes, cancer, coagulation and hemophilia treatments.The headquarters of Voluncis is in Paris, France, and has offices in Cambridge, ma.If you want more information visit the website www.voluntis.com [ Link
Insulia® uses the theraxium® voluntis technology platform that ensures the privacy of data and their safety, processes work and analytical flows, in addition to allowing interoperability with the rest of the platforms and IT devices.
Contacts - Media Consultations
Joe Travers Joseph.travers@voluntis.com +01 617-401-2420
(1) Diabetes Care Value Program Guarantees More Affordable, Higher-Qualy Diabetes Care.Express scripts.SEP 1, 2016
